We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA announced the approval of Johnson & Johnson's Spravato (esketamine), in conjunction with an oral antidepressant, for adults with treatment-resistant depression, with the nasal spray only available under a Risk Evaluation and Mitigation Strategy (R